TD Cowen raised the firm’s price target on Biogen (BIIB) to $215 from $175 and keeps a Buy rating on the shares. The firm said they reported results above conesnsus and they continue to think the company is undervalued for its cash flows, though acknowledge investors want better visibility on rev growth.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB: